Johnson & Johnson COVID-19 Vaccine

GPTKB entity

Predicate	Object
gptkbp:instanceOf	vaccine
gptkbp:alsoKnownAs	gptkb:Janssen_COVID-19_Vaccine
gptkbp:approvedBy	gptkb:Canada gptkb:European_Union gptkb:South_Africa gptkb:World_Health_Organization
gptkbp:clinicalTrialPhase	gptkb:ENSEMBLE
gptkbp:contains	recombinant, replication-incompetent adenovirus type 26 expressing the SARS-CoV-2 spike protein
gptkbp:countryOfOrigin	gptkb:United_States
gptkbp:developer	gptkb:Janssen_Pharmaceuticals
gptkbp:dosesRequired	1
gptkbp:efficacyAgainstModerateToSevereCOVID19	66%
gptkbp:efficacyAgainstSevereCOVID19	85%
gptkbp:emergencyServices	gptkb:United_States_Food_and_Drug_Administration
gptkbp:emergencyUseAuthorizationDate	2021-02-27
https://www.w3.org/2000/01/rdf-schema#label	Johnson & Johnson COVID-19 Vaccine
gptkbp:notRecommendedFor	children under 18 people with history of severe allergic reaction to vaccine ingredients
gptkbp:parentCompany	gptkb:Johnson_&_Johnson
gptkbp:rareSideEffects	gptkb:Guillain-Barré_syndrome thrombosis with thrombocytopenia syndrome
gptkbp:routeOfAdministration	intramuscular injection
gptkbp:shelfLife	2 years at -20°C 3 months at 2–8°C
gptkbp:sideEffect	fever fatigue headache muscle pain injection site pain
gptkbp:storage	2–8°C
gptkbp:target	gptkb:COVID-19
gptkbp:type	viral vector vaccine
gptkbp:vectorFor	gptkb:adenovirus_serotype_26_(Ad26)
gptkbp:WHOEmergencyUseListing	2021-03-12
gptkbp:withdrawnOrLimitedUse	gptkb:United_States
gptkbp:withdrawnOrLimitedUseDate	2023-05-07
gptkbp:bfsParent	gptkb:Janssen_COVID-19_Vaccine gptkb:Ad26.COV2.S
gptkbp:bfsLayer	7